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Abstract
Background: Chondrosarcoma is a disease that does not respond to conventional cytotoxic chemotherapy and
expression of MMP1 is a marker for a poor prognosis. The mechanism of increased MMP1 expression in
chondrosarcoma is not completely known. Our goal is to identify molecular pathways that could serve as
therapeutic targets. Chondrosarcoma become hypoxic as they grow, are capable of eliciting an angiogenic
response, and typically metastasize to the lungs. The present study determined the effect of hypoxia and
specifically HIF-1a on expression of CXCR4 and MMP1 and their role in chondrosarcoma cell invasion.
Results: CXCR4 and its ligand, SDF1, are upregulated in primary chondrosarcoma tumors compared to normal
articular cartilage, and CXCR4 was upregulated in chondrosarcoma cell line JJ compared to normal chondrocytes.
Hypoxia and specifically HIF-1a increased CXCR4 and MMP1 expression in JJ cell line and chondrosarcoma invasion
in vitro. The hypoxia mediated increase in MMP1 expression and chondrosarcoma invasion could be inhibited by
siRNA directed at HIF-1a or CXCR4, the CXCR4 inhibitor AMD3100, as well as with ERK inhibitor U0126 and ERK
siRNA.
Conclusions: Chondrosarcoma cell invasion is increased by hypoxia induced expression of CXCR4 and MMP1 and
is mediated by HIF-1a and ERK. Both invasion and MMP1 can be inhibited with CXCR4 blockade, suggesting that
CXCR4/SDF1 signaling may be a therapeutic target for chondrosarcoma.
Background
Chondrosarcoma is the second most common primary
malignant bone. It is a rare disease with a poor prog-
nosis, usually occurs in adults, and the cure rate for this
disease has not improved over the last several decades
[1,2]. For high grade tumors the cure rate has remained
at 10-25%[3]. The treatment for chondrosarcoma is sur-
gical resection; chemotherapy and radiation therapy are
not ordinarily used since chondrosarcoma are resistant
to these adjuvant modalities. In contrast to chondrosar-
coma, osteosarcoma, which usually occurs in adoles-
cents, is sensitive to chemotherapy and the cure rate has
increased from 20% to 75% with the advent of multia-
gent chemotherapy. However, in patients with either
tumor, the majority of those who are not cured suc-
cumb to lung metastases. Our efforts are directed at
elucidating the mechanisms of chondrosarcoma invasion
and metastasis.
Invasion, angiogenesis, migration, and metastasis are
intertwined processes regulated by overlapping molecu-
lar pathways. Chemokines and their receptors compose
one such pathway and are involved with cell trafficking,
migration, and proliferation. There are four groups of
chemokine receptors: C, CC, CXC, and CX3C. Chemo-
kine receptor four (CXCR4) is a seven-transmembrane
G-protein-coupled receptor, whose activation leads to
intracellular signaling cascades. CXCR4 is expressed in
dendritic cells, naïve T cells, NK cells, and monocytes
and is also the chemokine receptor most commonly
expressed in tumors. Within normal cells chemokine
receptors are important in immune cell function and
migration of stem cells to sites of injury. Within tumor
cells, chemokine receptor expression is related to devel-
opment of metastases preferentially to sites with expres-
sion of the corresponding chemokine[4]. The ligand for
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(SDF1) which is expressed in the lung and other sites of
metastases. CXCR4/SDF1 also indirectly promotes
tumor metastasis by mediating proliferation and migra-
tion of tumor cells and enhancing tumor-associated
angiogenesis [5]. The expression of chemokine receptors
has been mostly investigated in carcinoma and increased
levels of expression have been found in breast, gastric,
colorectal, and lung cancer. CXCR4 expression has also
been studied in melanoma, chondrosarcoma, and osteo-
sarcoma. In the latter expression of CXCR4 correlates
with overall survival, event-free survival, and metastasis
free survival [6] For review see [7,8].
Another factor that drives aggressive behavior in cancer
is hypoxia. Hypoxia is a signal that develops as tumors
outgrow their blood supply and results in a large number
of adaptive changes aimed at surviving in the hypoxic
environment as well as correcting the oxygen deficit.
HIF-1 is a dimeric transcription factor composed of HIF-
1 alpha and beta subunits. HIF-1 protein levels increase
as a result of decreased degradation of the oxygen sensi-
tive subunit HIF-1alpha. HIF-1 modulates changes in
gene expression during hypoxia. One of the better char-
acterized phenotypic changes induced by hypoxia is
angiogenesis, largely mediated by HIF-1 and vascular
endothelial growth factor (VEGF) which increases vessel
ingrowth from surrounding tissue into the tumor. Our
prior work has shown that grades II and III chondrosar-
coma express higher levels of HIF-1 and VEGF than
benign and grade I cartilage tumors[9] Grades II and III
chondrosarcoma are the tumors that metastasize and
have poor survival. Hypoxia is also known to increase
CXCR4 expression in other systems [10].
Tissue invasion by tumor cells and tumor induced
blood vessels also requires matrix metalloproteinases.
Specific tumors preferentially express different MMPs.
In chondrosarcoma, MMP1 is the dominant metallopro-
teinase that is expressed and is a marker for poor prog-
nosis [11]. However, the mechanisms of increased
MMP1 expression in chondrosarcoma are incompletely
understood.
Therefore, we investigated the expression of CXCR4
in normal chondrocytes, normal cartilage, chondrosar-
coma tissue, and chondrosarcoma cells (CS) and
hypothesized that CXCR4 is overexpressed in chondro-
sarcoma, is upregulated by hypoxia and specifically by
HIF-1, and increases the invasive phenotype by increas-
ing expression of MMP1.
Results
SDF1 and CXCR4 expression are increased in primary
chondrosarcoma
As a first step in evaluating the potential role of SDF1
and CXCR4 in chondrosarcoma biology, we analyzed
primary chondrosarcoma tissue and articular cartilage
f o re x p r e s s i o no fm R N Aa n dp r o t e i nf o rt h e s eg e n e s
using qRT-PCR and Western blotting. We found that
the median CXCR4 and SDF1 mRNA levels were 109
compared to 3 and 117 compared to 2 in the tumors
compared to normal tissue (Fig. 1A and 1B), and the
expression of CXCR4 correlated with tumor grade (p <
0.001, ANOVA). Western blot of CXCR4 expression for
a subset of primary tumors and normal cartilage showed
similar results. (Fig. 1C).
Effect of hypoxia on endogenous CXCR4 expression in
chondrosarcoma cell line
In chondrosarcoma cell line, the endogenous CXCR4
mRNA level was increased 6 fold compared to chondro-
cytes (Fig. 2A). Since tumors become hypoxic as they
grow, and hypoxia increases expression of genes related
to the malignant phenotype, we evaluated the expression
of CXCR4 under hypoxic conditions. CXCR4 mRNA
expression in JJ cells showed a progressive increase dur-
ing hypoxia (2% O2) that reached 16 fold after 48 h (Fig.
2B, C). Western blot confirmed the qRT-PCR results
(Fig. 2D).
HIF-1a regulates CXCR4 expression
In order to assess if Hif-1a specifically mediates the
increase in CXCR4 expression seen during hypoxia,
HIF-1a transfection was performed. CXCR4 mRNA level
increased by 3 fold relative to the empty vector control
(Fig. 3A). Conversely, knockdown of Hif-1a with specific
siRNA in JJ cultured in hypoxia decreased CXCR4
mRNA by 56% (Fig. 3C, D) and had the expected effect
on Hif-1a expression (Fig. 3B, D). Western Blot showed
the expressions of CXCR4 and Hif1a were reduced after
Hif-1a knockdown during hypoxia. (Fig. 3E).
Effect of hypoxia, HIF-1a and CXCR4 knockdown, and
CXCR4 blockade on invasion
To test whether overexpression of CXCR4 drives chon-
drosarcoma cell metastasis, an in vitro cell invasion
assay was performed. When cells were cultured in
hypoxia and an SDF1 gradient, cell invasion increased 2
fold compared to normoxia, p < 0.05. Knockdown of
Hif-1a or CXCR4 with specific siRNA completely
blocked this increase in invasion that occurs during
hypoxic culture (Fig. 4). Similarly, when the cells were
pretreated with the CXCR4 inhibitor AMD3100, the
hypoxia and SDF1 mediated increase in cell invasion
was blocked, whereas AMD3100 had no effect during
normoxia (Fig. 5).
Hypoxia and CXCR4 signaling increase MMP1 expression
and activity
Cell invasion is in part mediated by matrix metallopro-
teinases. Figure 6 shows the effects of hypoxia and
CXCR4 stimulation with SDF-1 or CXCR4 blockade
with AMD3100 on MMP1 mRNA expression and
secreted active MMP1 protein. Hypoxia increased
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increased to 23 fold by SDF1 stimulation. There was no
effect of SDF1 or AMD3100 during normoxia on
MMP1 mRNA level. AMD3100 blocked the SDF1
mediated increase in MMP1 mRNA during hypoxia (Fig
6A). Similarly, hypoxia and SDF1 increased active
MMP1 in conditioned media of cells cultured in
hypoxia. AMD3100 had no effect during hypoxia with-
out SDF1. AMD3100 in the presence of SDF1 had a
similar effect as the MMP inhibitor O-phenanthroline
(Fig 6B).
Downstream effects of hypoxia and CXCR4/SDF-1 are
mediated through ERK signaling
In order to assess the role of MAP kinases in CXCR4/
SDF1 signaling, time course analysis of MAP kinase
expression after SDF1 exposure was performed. SDF1
stimulation during hypoxia transiently increased phos-
phorylated ERK which reached a peak at 10 minutes.
The increase in phosphorylated ERK could be inhibited
by MEK (ERK) inhibitor U0126 (Fig. 7A). There was
less effect of SDF1 on phosphorylated JNK and no effect
on p38. SDF1 stimulation during hypoxia also increased
MMP1 protein expression. Both the CXCR4 inhibitor
AMD3100, the ERK inhibitor U0126, and ERK1/2
siRNA inhibited MMP1 protein expression (Fig. 7B,
Additional file 1). The SDF1 mediated increase in cell
invasion during hypoxia was also inhibited by U0126
and ERK1/2 siRNA, but not by the other MAP kinase
inhibitors SP600125 and SB203580 (Fig 7C, D, Addi-
tional file 1).
Discussion
A better understanding of the mechanisms underlying
invasive behavior of a cancer is an important first step
in developing improved treatment strategies. This study
provides the first indication that CXCR4 is regulated by
Figure 1 Expression of CXCR4 and SDF-1 in normal cartilage (CL) and chondrosarcoma tissue (CS). A and B, the endogenous mRNA
levels of CXCR4 and SDF-1were quantified by qRT-PCR and normalized to 18S. Graphs represent the median of CXCR4 and SDF-1 levels with the
25th-75th percentiles, *, p < 0.001, CS (n = 16) versus CL (control, n = 8). C, CXCR4 protein level in CL and CS. Whole cell lysates from two CL
and three CS specimens were subject to Western blot to detect CXCR4 protein. Representative blot is shown from one of three independent
experiments. Actin was used as the loading control.
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We also show that increased CXCR4 signaling regulates
expression of MMP1, a factor known to be involved
with chondrosarcoma metastasis and a marker for poor
prognosis[11]. Overexpression of CXCR4 has been
reported in a variety of tumors, primarily carcinoma. In
carcinoma, CXCR4 expression mediates metastasis to
bone, which has relatively high levels of SDF1. In chon-
drosarcoma, it is possible that local SDF1 stimulates
local tumor growth in a paracrine manner, and for
those cells which gain access to the circulation, may
also partially account for the tendency of these tumors
to develop lung metastases, since the lung also contains
high levels of SDF1. Factors such as MMP1 mediate
local migration out of the microenvironment, ie stroma
for carcinoma and bone for chondrosarcoma, and into
the circulation. Factors such as CXCR4 mediate homing
and growth at distant sites. Within sarcoma, CXCR4
expression has been detected in osteosarcoma [6,12]and
recently in chondrosarcoma[13]. Our results confirm the
expression of CXCR4 in both chondrosarcoma tissue
and cell lines and also show that CXCR4 expression was
higher in high grade tumors, that hypoxia and HIF-1a
enhance CXCR4/SDF1 mediated invasion through upre-
gulation of CXCR4 expression, and that CXCR4/SDF1
signaling increases invasion through ERK mediated
increase in MMP1 expression and activity.
Hypoxia, primarily acting through HIF-1a, elicits a
wide spectrum of changes in gene expression that con-
tribute to the metastatic phenotype of cancer cells.
Hypoxia and Hif-1a have been shown to upregulate
CXCR4 in carcinomas such as lung cancer [14], oral
squamous cell carcinoma[15], breast carcinoma [16],
and renal cell carcinoma [17]. The mechanism of Hif-1a
regulation of CXCR4 is through direct binding to the
CXCR4 promoter [18]. Our results show that HIF-1a
also upregulates CXCR4 in chondrosarcoma. Interest-
ingly, during chondrogenic differentiation CXCR4 is
downregulated[19]. Although chondrosarcoma share
some markers of the cartilage phenotype, as cells
become malignant, some repressed genes will be reex-
pressed. CXCR4 has been shown to be involved with
cell migration and invasion in many systems. The data
include in vitro invasion and migration assays as well as
xenograft models of metastatic disease in which block-
ade of CXCR4 with drugs, peptides, or antibodies can
Figure 2 CXCR4 expression during normoxia and hypoxia in chondrosarcoma cells. A, CXCR4 mRNA expression in chondrosarcoma cell
line JJ and normal chondrocytes (CH) in normoxia was analyzed by qRT-PCR. *, p < 0.02. B, CXCR4 mRNA expression in JJ cells in normoxia (N)
and hypoxia (H) for 24 h (N1, H1) or 48 h (N2, H2) was quantitated by qRT-PCR. *, p < 0.05, compared to N1. #, p < 0.001, compared to N2. C,
Representative electrophoresis of qRT-PCR products from B. Odd numbered lanes normoxia, even numbered lanes hypoxia; 24 and 48 h. Lanes
1-4: internal control (18S), lanes 5-8: Hif-1a, lanes 9-12: CXCR4. M is 50 bp molecular marker. D, Representative Western Blot of three independent
experiments to detect CXCR4 and Hif-1a in JJ cells. Cell lysates were obtained after 48 h of culture in normoxia or hypoxia. Actin was used as
loading control.
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dent of CXCR4, MMP1 has also been shown to be
involved with tissue invasion and development of metas-
tases. MMP1 is also known to be upregulated by
hypoxia and HIF-1a in breast and lung cancer cells
[20,21], and also by CXCR4 in Nk cells [22] and pros-
tate cancer cells [23]. However, this project is the first
to link the combined effects of HIF-1a on CXCR4 and
MMP1 expression and the indirect effect of HIF-1a on
MMP1 expression acting through CXCR4, which inde-
pendently increases MMP1 in chondrosarcoma cells.
T h er o l eo fM M P 1i nc h o n d r o s a r c o m ai n v a s i o na n d
its role as a poor prognostic indicator have been known
for some time [11,24]. Inhibition of MMP1 with siRNA
has been shown to decrease chondrosarcoma cell inva-
s i o n[ 2 5 - 2 7 ] .W eh a v es h o w nt h a to n em e c h a n i s mo f
increased MMP1 in chondrosarcoma is mediated
through CXCR4 signaling, which is amplified by
hypoxia, and is mediated by ERK, but not other MAP
kinases. siRNA directed against HIF-1a, CXCR4, ERK;
CXCR4 blockade with AMD3100; or ERK inhibitor
U0126 all efficiently inhibited the increase in invasion of
chondrosarcoma cells during hypoxia. A previous study
of CXCR4 in chondrosarcoma invasion during normoxia
showed that CXCR signaling increased expression of
alphavbeta3 integrin, also through ERK, and that
Figure 3 Hif-1a regulates CXCR4 expression. A and B, CXCR4 and HIF-1a expression after transfection with HIF-1a. JJ cells were transfected
with HIF-1a expression construct or empty vector (EV). After 48 h, CXCR4 and HIF-1a expression was quantified by qRT-PCR; *, p < 0.02 and p <
0.01 respectively. C, D and E, CXCR4 and HIF-1a expression after HIF-1a knockdown. JJ cells were transfected with si-RNA directed against HIF-1a
(HIF-1a si, lanes 2,4,6) or scramble siRNA (con-si, lanes 1,3,5) and CXCR4 and HIF-1a expression analyzed after 72 h of hypoxia with qRT-PCR (C, D)
and Western blotting (E); *, p < 0.001. M is 50 bp molecular marker.
Sun et al. Molecular Cancer 2010, 9:17
http://www.molecular-cancer.com/content/9/1/17
Page 5 of 11Figure 4 Effect of Hif-1a and CXCR4 knockdown on the invasion of chondrosarcoma cells. JJ cells were cultured in normoxia (mock) or
hypoxia for 48 h after transfection with scramble siRNA (Con-si), or siRNA directed against Hif-1a or CXCR4. Invasion assay was then performed
as described in Methods. #, p < 0.05, compared to Mock; *, p < 0.01, **, p < 0.05, compared with Con-si.
Figure 5 Effect of hypoxia and CXCR4 inhibition on the invasion of chondrosarcoma cells. JJ cells were cultured under normoxia or in
hypoxia with 10 ng/ml SDF1 in the presence or absence of 0.1 μM of AMD3100 for 48 h (AMD3100 was added 2 h before SDF1) before
performing the invasion assay, which was also performed during normoxia or hypoxia with or without AMD3100. *, p < 0.01; #, p < 0.05
compared to Hypoxia. Upper panel, bar graphs represent data from three independent experiments. Lower panel, representative photographs of
stained cells on the lower side of matrigel membrane from one of three experiments. Original magnifications, 100×.
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drosarcoma invasion in vitro[13]. Therefore, CXCR4
affects chondrosarcoma invasion through upregulation
of multiple genes including alphavbeta3 integrin and
MMP1. In other tumors and chondrosarcoma (Addi-
tional file 2), CXCR4 signaling upregulates other MMPs
such as MMP-2, 8 and -9 and -13[28,29]. Since CXCR
signaling upregulates multiple genes related to metasta-
sis and since clinical MMP inhibition is not currently
feasible, whereas CXCR4 blockade is possible with drugs
such as AMD3100, CXCR4 may be a fruitful therapeutic
target to inhibit some of the metastatic potential of
chondrosarcoma cells.
Conclusions
We present data that shows hypoxia mediated increase
in MMP1 expression and chondrosarcoma invasion is
partially mediated by CXCR4 signaling. CXCR4 block-
ade can inhibit the effects of hypoxia on MMP1
expression and chondrosarcoma invasion in vitro, sug-
gesting that CXCR4 blockade could be a therapeutic tar-
get to inhibit chondrosarcoma invasion and metastasis.
The effectiveness of this strategy requires in vivo
confirmation.
Methods
Tissue
Articular cartilage, chondrosarcoma tissue, and cancel-
lous bone were obtained from surgical specimens, and
either preserved in RNAlater Solution (Applied Biosys-
tems, Foster City, CA) or snap frozen in liquid nitrogen
for later use. There were 8 articular cartilage specimens
a n d1 6c h o n d r o s a r c o m a( 3g r a d eI ,5g r a d eI I ,a n d8
grade III). IRB approval was obtained.
Cell lines and cell culture
Human chondrocytes isolated from normal adult articu-
lar cartilage and chondrosarcoma (CS) cell line JJ (a gift
from Dr. Joel Block, Rush Medical School, Chicago, IL)
Figure 6 SDF1 increases MMP1 mRNA level and MMP1 activity during hypoxia. Tumor cells were cultured on matrigel with only medium
(MOCK), SDF1 (10 ng/ml), AMD3100 0.1 μM, or SDF1+AMD3100 (AMD3100 was added 2 h before SDF1), or SDF1 + mmpi (MMPs inhibitor O-
phenanthroline, 10 nM) for 24 h. Conditioned medium was then collected for ELISA and cells were harvested for RNA isolation. A, MMP-1 mRNA
level was measured by qRT-PCR (*, p < 0.001, compared to Mock in hypoxia; #, p < 0.001, compared to SDF1 in hypoxia). B, active MMP-1 was
measured in conditioned media by ELISA (*, p < 0.01, compared to Mock-H in hypoxia; **, p < 0.05, compared to SDF1 in hypoxia).
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Page 7 of 11Figure 7 MAP kinase is activated by SDF1 and ERK inhibitor reduces MMP1 production and CS cell invasion. JJ cells were cultured with
10 ng/ml SDF1 or pretreated for 2 h with 10 μmol/L U0126, 40 nM SP600125, or 100 nM SB203580 in hypoxia. A, Whole cell lysates at indicated
time points were subjected to Western blot analysis for total and phophorylated ERK, JNK, and p38. B, Cell lysates were used for Western blot
analysis of total MMP-1 after 48 h, SDF1 10 ng/ml, AMD3100 0.1 μM, or U0126 10 μmol/L in hypoxia. C, JJ cells were cultured for 24 h in
hypoxia with DMSO (Mock), SDF1 10 ng/ml alone or after 2 h pretreatment with MAP kinase inhibitors (U0126 10 μM, SP600125 40 nM,
SB203580 2 μM), then invasion assay was performed for 72 h in hypoxia with SDF1 50 ng/ml in lower chamber only and inhibitors in both
chambers. *, p < 0.01, compared to Mock; **, p < 0.05, compared to SDF-1. Bar graphs represent data from three independent experiments. D,
representative photographs of stained cells on the lower side of matrigel membrane from one of three experiments in C. Original magnification
100×.
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MEM, 20% F12) with 10% FBS. All cells were cultured
in a humidified incubator (NuAire Inc, Plymouth MN)
under 5% CO2 and either normoxia (ambient oxygen) or
hypoxia (2% O2) [30]. JJ was derived from a human
grade II chondrosarcoma[31]. The drugs and inhibitors
used were: AMD3100 (Sigma Chemical Company St.
Louis, MO), human recombinant SDF-1 (R&D Systems,
Minneapolis, MN), MMP inhibitor O-phenanthroline
(Sigma), MAP kinase inhibitors: MEK1/2 inhibitor
U0126 (Cell Signaling, Beverly, MA), JNK inhibitor
SP600125 (A.G. Scientific Inc., San Diego, CA), p38
inhibitor SB203580 (BioMol International, Plymouth
Meeting, PA) or DMSO (Sigma), solvent for the
inhibitors.
Transfections
Cells were transiently transfected with an expression
construct for human Hif-1a in pcDNA3.1(+) vector
(Invitrogen, Carlsbad, CA), (a gift from Hirouki Kato
PhD, Tokyo Metropolitan Institute of Medical Science,
Tokyo, Japan), or empty vector using Fugene HD
(Roche, Indianapolis, IN) in 6 or 12 well plates 24 h
after seeding. Cells were then incubated for 48 h and
harvested for the following experiments.
RNA interference (siRNA)
Cells were transfected with Hif-1a siRNA (Qiagen,
Valencia, CA), CXCR4 siRNA (Dharmacon, Lafayette,
CO), ERK1/2 siRNA(Cell Signaling Technology, Inc.,
Beverly, MA) or control siRNA by HiPerFect transfec-
tion reagent (Qiagen). RNA and protein were obtained
72 h after transfection for qRT-PCR and Western Blot
analysis.
Real-time RT-PCR (qPCR)
RNA was isolated from cells with RNAqueous Kit
(Ambion, Austin, TX) or tissues with Trizol Reagent
(Invitrogen). After treatment with TURBO DNase
(Ambion), one microgram of RNA was reverse tran-
scribed with random hexamers to obtain first-strand
cDNA using iScript cDNA kit (Bio-Rad, Philadelphia,
PA). The quantification of mRNA for Hif-1a, CXCR4,
SDF-1, and MMP1 was performed by two-step real-time
quantitative RT-PCR (Qiagen). Primers (5’-3’) for Hif-1a
were: forward, ctc aaa gtc gga cag cct ca; reverse, ccc
tgc agt agg ttt ctg ct; for CXCR4, forward: gtc cac gcc
acc aac ag, reverse: ctg ttg gtg gcg tgg ac; for SDF-1, for-
ward: cgt gct ggt cct cgt gct gac; reverse: gct ttc tcc agg
tac tcc tg; for MMP1, forward: gag caa aca cat ctg acc
tac agg a; and reverse, ttg tcc cga tga tct ccc ctg aca;
18S was used as an internal control since it has been
shown to be the optimal reference gene[32]. Amplifica-
tion conditions were as follows: 2 min preincubation at
50°C, 10 minutes at 95°C for enzyme activation, and 40
cycles at 95°C denaturation for 10 s, 55°C annealing for
30 s (59°C for MMP1) and 72°C extension for 30 s. The
comparative threshold cycle (Ct) method, i.e., 2
-ΔΔCt
method was used for the calculation of fold amplifica-
tion[33]. Each experiment was evaluated with three PCR
reactions and each experiment was repeated three times.
Data are presented as mean value ± SD.
Western Blot Analysis
Protein from cell lysates of tissues or cells were sepa-
r a t e dv i aS D S - P A G Ea n dp r o b e dw i t ha n t i b o d i e sf o r
CXCR4, MMP1, actin (Santa Cruz Biotechnology, Santa
C r u z ,C A ) ;a n da n t i b o d i e sf o rH i f - 1 a ,p - E R K ,E R K ,p -
JNK, JNK, p-p38, and p38 (Cell Signaling Technology,
Inc.). Western Blot analyses were performed as pre-
viously described [10]. Protein concentrations were
determined using the Bio-Rad Quick Start Bradford pro-
tein assay (Bio-Rad, Hercules, CA) and the equivalent of
forty μg of protein were subjected to SDS-PAGE (Lonza
Inc., Allendale, NJ).
ELISA Assay
After treatment, cells were cultured O/N in FBS free
medium and the conditioned media (CM) from CS cells
was concentrated using Centricon-30 centrifugal filter
device (Millipore, Billerica, MA). The amount of active
MMP1 was detected using Human Active MMP1 Fluor-
escent Assay kit (R&D Systems, Minneapolis, MN)
according to the manufacturer’s instructions. Active
MMP1 in the CM was measured in duplicate for each
sample and normalized to the cell number at the end of
the culture period. Each experiment was repeated three
times.
Tumor cell invasion assay
Invasive activity of CS cells was analyzed with matrigel
coated BD Falcon Cell Culture Inserts (BD Biosciences,
Bedford, MA). Briefly, 180 μlo fB DM a t r i g e lM a t r i x
Growth Factor Reduced (BD Biosciences, Bedford, MA)
diluted 1:3 with serum-free medium was used to coat 8
μm pore size 12-well inserts and incubated at 37°C for 2
h. After various treatments, during which cells are cul-
tured O/N without FBS, the cells were harvested by
trypsinization, counted, and resuspended in complete
medium containing 1% FBS at a concentration of 10
6/
ml. 800 μl containing 8 × 10
5 cells were added to each
of the upper wells. 1.5 ml of 5% FBS complete medium
containing recombinant SDF1 (50 ng/ml, R&D Systems)
was added to the lower wells. After incubating for 72 h
in hypoxia, cells that had invaded across the membrane
were stained with Cell Stain Solution (Millipore),
washed, photographed, then lysed and cell number
quantitated by absorbance at 560 nm on a standard
microplate reader. The invasion index was calculated by
normalizing to the number of cells invading when the
lower well has no SDF1 or FBS.
Statistics
All the experiments were repeated at least 3 times. Sta-
tistical analysis was performed with GraphPad Prism, v
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and CXCR4 expression in different grades of chondro-
sarcoma were analyzed with one-way ANOVA. Post test
comparisons were made with Bonferroni correction.
Experiments with two groups were analyzed with the
Student’s t-test. The null hypothesis of no difference
was rejected at a significance level of 5%.
Additional file 1: Effect of ERK knockdown on MMP1 expression
and invasion in chondrosarcoma cells. A, Whole cell lysates from JJ
cells were used for Western blot analysis of total MMP-1 after 48 h in
hypoxia after ERK siRNA transfection. B, JJ cells were transfected with ERK
siRNA. After 48 hours in hypoxia, invasion assay was performed as
described in Methods.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-17-
S1.PPT]
Additional file 2: MMPs expressed in chondrosarcoma cells. JJ cells
were cultured in hypoxia 48 h without (mock) or with SDF-1 for 2 days.
*, p < 0.02, **, p < 0.03, #, p < 0.04.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-17-
S2.PPT]
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